Company intelligence / Profile preview

National Heart Centre Singapore

Ownership: Private
Development stage: Other

Overview

NHCS has pioneered numerous clinical milestones in Singapore’s cardiovascular care including the first local heart transplant (1990), first drug-coated stent implantation (2002), and first robotic cardiac surgery. It continues to lead with innovative technologies such as the SENSE AI platform for rapid coronary artery disease diagnosis[1][10].

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologicSmall moleculeNon-pharmacological therapy
Industry: Academic Hospital/University/Research

Partnerships

ASTAR Institute for Infocomm Research (ASTAR I²R) – co-developer of SENSE AI platform[10]Collaborates with major hospitals in Singapore including National University Hospital and Tan Tock Seng Hospital on technology rollouts[10]

Beyond the preview

Go deeper on National Heart Centre Singapore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on National Heart Centre Singapore.

Explore the full profile